Literature DB >> 17391432

Structure-function relationships in alpha-galactosidase A.

Scott C Garman1.   

Abstract

UNLABELLED: With recent interest in the molecular mechanisms responsible for Fabry disease, the number of known mutations in the GLA gene which encodes alpha-galactosidase A has expanded considerably. Combining a large database of Fabry disease-causing mutations with the recently determined crystal structure of human alpha-galactosidase A allows for a new understanding of the atomic defects in the protein responsible for Fabry disease. We have conducted a systematic survey of the known Fabry disease-causing mutations and analyzed the mutations in the context of the alpha-galactosidase A structure. We have applied quantitative methods for identifying the plausible effect of each mutation on the alpha-galactosidase A protein. We present the analysis of 331 different defects in the GLA gene leading to non-native proteins in patients with Fabry disease. These mutations include 278 missense mutations, 49 nonsense mutations, and four single amino acid deletions.
CONCLUSION: Over half of the residues in the protein have been found to have changes in patients with Fabry disease. Most of these genetic mutations lead to disruption of the hydrophobic core of the protein, thus Fabry disease is primarily a disease of protein-folding. Further understanding of alpha-galactosidase A, one of the best studied members of the lysosomal storage disease family, will lead to increased understanding of other lysosomal storage diseases and other protein-folding diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17391432      PMCID: PMC3065945          DOI: 10.1111/j.1651-2227.2007.00198.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  76 in total

1.  Five novel mutations in fourteen patients with Fabry Disease.

Authors:  K M Rosenberg; R Schiffmann; C Kaneski; R O Brady; S A Sorensen; L Hasholt
Journal:  Hum Mutat       Date:  2000-02       Impact factor: 4.878

2.  [Fabry disease: data from four families].

Authors:  P H Slee; L J van Boven; D S Slee
Journal:  Ned Tijdschr Geneeskd       Date:  2000-12-09

3.  The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000.

Authors:  A Bairoch; R Apweiler
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

4.  Editing of human alpha-galactosidase RNA resulting in a pyrimidine to purine conversion.

Authors:  F J Novo; A Kruszewski; K D MacDermot; G Goldspink; D C Górecki
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

5.  Two novel mutations (L32P) and (G85N) among five different missense mutations in six Danish families with Fabry's disease.

Authors:  K M Madsen; L Hasholt; S A Sørensen; M L Fermér; N Dahl
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

6.  Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease.

Authors:  A K Topaloglu; G A Ashley; B Tong; J Shabbeer; K H Astrin; C M Eng; R J Desnick
Journal:  Mol Med       Date:  1999-12       Impact factor: 6.354

7.  Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice.

Authors:  Y A Ioannou; K M Zeidner; R E Gordon; R J Desnick
Journal:  Am J Hum Genet       Date:  2000-12-13       Impact factor: 11.025

8.  Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes.

Authors:  P Ashton-Prolla; B Tong; J Shabbeer; K H Astrin; C M Eng; R J Desnick
Journal:  J Investig Med       Date:  2000-07       Impact factor: 2.895

9.  Identification of four novel mutations in five unrelated Korean families with Fabry disease.

Authors:  J K Lee; G H Kim; J S Kim; K K Kim; M C Lee; H W Yoo
Journal:  Clin Genet       Date:  2000-09       Impact factor: 4.438

10.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

View more
  18 in total

1.  Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Authors:  Silvia Lombardi; Mattia Ferrarese; Saverio Marchi; Paolo Pinton; Mirko Pinotti; Francesco Bernardi; Alessio Branchini
Journal:  RNA Biol       Date:  2019-10-15       Impact factor: 4.652

2.  Impact of cysteine variants on the structure, activity, and stability of recombinant human α-galactosidase A.

Authors:  Huawei Qiu; Denise M Honey; Jonathan S Kingsbury; Anna Park; Ekaterina Boudanova; Ronnie R Wei; Clark Q Pan; Tim Edmunds
Journal:  Protein Sci       Date:  2015-07-14       Impact factor: 6.725

3.  Impact of immobilization technology in industrial and pharmaceutical applications.

Authors:  Mohamed E Hassan; Qingyu Yang; Zhigang Xiao; Lu Liu; Na Wang; Xiaotong Cui; Liu Yang
Journal:  3 Biotech       Date:  2019-11-08       Impact factor: 2.406

4.  Awareness of Fabry disease among rheumatologists--current status and perspectives.

Authors:  Rolando Cimaz; Severine Guillaume; Max J Hilz; Gerd Horneff; Bernhard Manger; J Carter Thorne; Anette Torvin Møller; Nico M Wulffraat; Johannes Roth
Journal:  Clin Rheumatol       Date:  2011-04       Impact factor: 2.980

5.  The Modulatory Effects of the Polymorphisms in GLA 5'-Untranslated Region Upon Gene Expression Are Cell-Type Specific.

Authors:  Susana Ferreira; Carlos Reguenga; João Paulo Oliveira
Journal:  JIMD Rep       Date:  2015-03-13

6.  Catalytic mechanism of human alpha-galactosidase.

Authors:  Abigail I Guce; Nathaniel E Clark; Eric N Salgado; Dina R Ivanen; Anna A Kulminskaya; Harry Brumer; Scott C Garman
Journal:  J Biol Chem       Date:  2009-11-25       Impact factor: 5.157

7.  The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.

Authors:  E R Benjamin; J J Flanagan; A Schilling; H H Chang; L Agarwal; E Katz; X Wu; C Pine; B Wustman; R J Desnick; D J Lockhart; K J Valenzano
Journal:  J Inherit Metab Dis       Date:  2009-04-18       Impact factor: 4.982

8.  Pharmacological chaperones for human α-N-acetylgalactosaminidase.

Authors:  Nathaniel E Clark; Matthew C Metcalf; Daniel Best; George W J Fleet; Scott C Garman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

9.  Structural characterization of mutant alpha-galactosidases causing Fabry disease.

Authors:  Kanako Sugawara; Kazuki Ohno; Seiji Saito; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-07-17       Impact factor: 3.172

10.  The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: Report from the SSIEM Adult Metabolic Physicians Group.

Authors:  S Sirrs; C Hollak; M Merkel; A Sechi; E Glamuzina; M C Janssen; R Lachmann; J Langendonk; M Scarpelli; T Ben Omran; F Mochel; M C Tchan
Journal:  JIMD Rep       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.